- In patients with nonmetastatic, castration-resistant prostate cancer (CRPC), enzalutamide maintains low baseline pain and health-related QoL (HRQoL) scores.
- Enzalutamide delays pain progression, worsening of urinary and bowel symptoms.
Why this matters
- Enzalutamide prolonged metastasis-free survival in PROSPER study.
- Patient-reported outcomes from PROSPER study.
- 1401 men with nonmetastatic CRPC, PSA doubling time ≤10 months received androgen deprivation therapy with either enzalutamide or placebo.
- Funding: Astellas Pharma, Inc.
- Median follow-up: enzalutamide group, 18.5 months; placebo group, 15.1 months.
- Brief Pain Inventory Short Form:
- Mean scores remained stable and similar at all timepoints.
- Time to pain progression was longer with enzalutamide (P=.028).
- European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire:
- Mean symptom scores remained stable and similar except at weeks 65 and 81, where urinary symptom score was significantly better with enzalutamide (P=.028 and .0251, respectively).
- Functional Assessment of Cancer Therapy-Prostate:
- Mean scores were similar (P=.184).
- EuroQoL 5-Dimensions 5-Levels health questionnaire visual analogue scale:
- Mean scores remained stable and similar between groups except at weeks 65 and 81 (P=.024 and .022, respectively, favoring enzalutamide).
- Time to worsening of urinary and bowel symptoms was significantly longer with enzalutamide.
- Lack of data after treatment discontinuation.